National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Glasdegib (Daurismo®) in combination with low-dose cytarabine. HTA ID: 20041

Glasdegib is indicated, in combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy.

 

NCPE Assessment Process Complete
Rapid review commissioned 07/09/2020
Rapid review completed 09/10/2020
Rapid Review outcome Reimbursement is not recommended at this time, due to a lack of evaluable evidence*.

 

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.